Expanding the contraceptive pharmacology evidence base for people with higher body weight
Expanding the contraceptive pharmacology evidence base for people with higher body weight supports researchers studying hormonal contraception in this population to improve person-centered contraceptive care.
Funder: Society for Family Planning
Due Dates: October 7, 2026 (Applications open) | December 1, 2026 (Application deadline, 8:59 pm PT / 11:59 pm ET)
Funding Amounts: Up to $225,000 per project for up to 18 months; smaller projects up to $75,000 also anticipated
Summary: Supports research on hormonal contraceptive pharmacology in people with higher body weight to advance evidence-informed, person-centered contraceptive care.
Key Information: Awards go only to tax-exempt organizations on behalf of a named principal investigator, for projects focused on people in the US.
Description
The Society for Family Planning supports research on the clinical pharmacology of hormonal contraceptives, including pharmacokinetics and pharmacodynamics, in people with higher body weight. This population has often been excluded from contraceptive clinical trials, leaving important evidence gaps. Supported by an anonymous foundation, the opportunity seeks empirical research with a clear path to influencing clinical practice, health services delivery, and structures supporting evidence-informed, person-centered contraceptive care.
Research interests include differences in metabolism and clearance across oral contraceptive formulations, interactions between oral or injectable GLP-1 receptor agonists and hormonal contraception, and how progestin-only pills function among people with higher body weight. The Society encourages measures beyond BMI and attention to social location, weight-related stigma, equity, and researchers’ identities and lived experiences.
